Determination of thalidomide concentration in human plasma by liquid chromatography‑tandem mass spectrometry

Bai,Nan; Cui,Xiang‑Yong; Wang,Jin; Sun,Chun‑Guang; Mei,He‑Kun; Liang,Bei‑Bei; Cai,Yun; Song,Xiu‑Jie; Gu,Jing‑Kai; Wang,Rui

doi:10.3892/etm.2012.847

Determination of thalidomide concentration in human plasma by liquid chromatography‑tandem mass spectrometry

Authors:
- Nan Bai
- Xiang‑Yong Cui
- Jin Wang
- Chun‑Guang Sun
- He‑Kun Mei
- Bei‑Bei Liang
- Yun Cai
- Xiu‑Jie Song
- Jing‑Kai Gu
- Rui Wang
View Affiliations

Affiliations: The Center of Medicine Clinical Research, Chinese PLA General Hospital, Beijing 100853, P.R. China, Research Center for Drug Metabolism, Jilin University, Changchun 130023, P.R. China
Published online on: November 30, 2012 https://doi.org/10.3892/etm.2012.847
Pages: 626-630

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A rapid, sensitive and specific analytical method based on high‑performance liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) has been developed for the determination of thalidomide concentration in human plasma. The analyte and internal standard were extracted by liquid‑liquid extraction with ether‑dichloromethane (3:2, v/v) and separated on a TC‑C18 column using methanol‑10 mM ammonium acetate‑formic acid (60:40:0.04, v/v/v) as the mobile phase at a flow rate of 0.9 ml/min. The detection was performed using an API 4000 triple quadrupole mass spectrometer in the positive electrospray ionization (ESI) mode and completed within 3.0 min. The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide. The calibration curve exhibited a linear dynamic range of 2‑1500 ng/ml (r>0.9991). The intra‑and inter‑day precisions (as relative standard deviation; RSD) were 6.8‑13.5% and 4.3‑5.0% respectively and the accuracy (as relative error; RE) was 2.0‑3.5%. The recoveries and matrix effects were satisfactory in all the biological matrices examined. This method was successfully used in a pharmacokinetic study of thalidomide in healthy male volunteers receiving an oral administration of a 200‑mg dose.

View Figures

View References

1.	Calabrese L and Resztak K: Thalidomide revisited: pharmacology and clinical applications. Expert Opin Investig Drugs. 7:2043–2060. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Laffitte E and Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 3:47–56. 2004. View Article : Google Scholar
3.	Kamikawa R, Ikawa K, Morikawa N, Asaoku H, Iwato K and Sasaki A: The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. Biol Pharm Bull. 29:2331–2334. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Yakoub-Agha I, Attal M, Dumontet C, et al: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myélome (IFM). Hematol J. 3:185–192. 2002.PubMed/NCBI
5.	Barillé-Nion S, Barlogie B, Bataille R, et al: Advances in biology and therapy of multiple myeloma. Hematology. Am Soc Hematol Educ Program. 248–278. 2003.PubMed/NCBI
6.	Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A and Onel KB: Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 145:856–857. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Heine RG, Cameron DJ, Chow CW, Hill DJ and Catto-Smith AG: Esophagitis in distressed infants: poor diagnostic agreement between esophageal pH monitoring and histopathologic findings. J Pediatr. 140:14–19. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Akkoc N, van der Linden S and Khan MA: Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 20:539–557. 2006. View Article : Google Scholar : PubMed/NCBI
9.	van der Horst-Bruinsma IE, Clegg DO and Dijkmans BA: Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol. 20(6 Suppl 28): S67–S70. 2002.PubMed/NCBI
10.	Zlnay D, Zlnay M and Rovenský J: Ankylosing spondylitis - the current situation and new therapeutic options. Vnitr Lek. 52:730–735. 2006.(In Slovak).
11.	Mansfield JC, Parkes M, Hawthorne AB, et al: A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther. 26:421–430. 2007.PubMed/NCBI
12.	Raza A: Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 50:229–235. 2000.
13.	Brocard A, Barbarot S, Milpied B and Stalder JF: Thalidomide in the treatment of chronic discoid lupus erythematosus. Ann Dermatol Venereol. 132:853–856. 2005.(In French).
14.	Bang D: Treatment of Behçet’s disease. Yonsei Med J. 38:401–410. 1997.
15.	Chung F, Lu J, Palmer BD, et al: Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res. 10:5949–5956. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Eriksson T, Björkman S, Fyge A and Ekberg H: Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr. 582:211–216. 1992. View Article : Google Scholar : PubMed/NCBI
17.	Huang YJ, Liao JF and Tsai TH: Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed Chromatogr. 19:488–493. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Teo SK, Colburn WA and Thomas SD: Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol. 39:1162–1168. 1999.PubMed/NCBI
19.	Saccomanni G, Turini V, Manera C, et al: High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. J Pharm Biomed Anal. 48:447–451. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Yang X, Hu Z, Chan SY, et al: Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal. 39:299–304. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Chen TL, Vogelsang GB, Petty BG, et al: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos. 17:402–405. 1989.PubMed/NCBI
22.	Zhou S, Li Y, Kestell P and Paxton JW: Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 785:165–173. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Toraño JS, Verbon A and Guchelaar HJ: Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 734:203–210. 1999.
24.	Teo SK, Chandula RS, Harden JL, Stirling DI and Thomas SD: Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 767:145–151. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Teo SK, Harden JL, Burke AB, et al: Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 29:1355–1357. 2001.PubMed/NCBI